Home/Investors

Innovative and pragmatic,
honest and transparent.

iXensor Co., Ltd. (ticker 6734.TWO) is committed to open, transparent communication with investors. This section provides links and contacts for corporate governance, financial information, material announcements and shareholder services.

6734
TWO · Ticker
2012
Founded
2019
Listed (Emerging)
iXensor proactive health platform
INVESTOR INFORMATION

Public information, all in one place

All of the company's financial reports, material announcements and shareholder-meeting documents are disclosed on MOPS as required by law. The main information portals are below.

Financial information

Quarterly consolidated reports, annual reports and monthly revenue are disclosed on MOPS as required.

Go to MOPS

Material announcements

Material announcements are published on MOPS in real time as required, ensuring timely and fair disclosure.

Search announcements

Shareholder services

Share transfers, dividend distribution and shareholder meetings are handled with the help of the company's share registrar.

TDCC IR platform
CORPORATE GOVERNANCE

Company profile

Company name
iXensor Co., Ltd.
iXensor Co.,Ltd.
Ticker
6734.TWO
Biotech & medical · listed on Emerging board, 2019
Chairman & CEO
Carson Chen, Ph.D.
Carson Chen,Ph.D.
Founded
August 2012
Main business: R&D, manufacturing and sales of medical devices
Address
6F., No.9, Aly. 2, Ln. 35, Jihu Rd., Neihu Dist., Taipei
+886-2-8751-1335
Share registrar
Capital Securities Corporation
B2, No.97, Sec. 2, Dunhua S. Rd., Da'an Dist., Taipei · (02) 2702-3999
GROWTH STRATEGY

The long-term direction we believe in

Below is the company's long-term strategic direction as communicated publicly. For specific financial figures and operational outlook, please refer to the official announcements on MOPS.

01

Proactive health platform

With the PixoTech® platform at its core, we connect home clinical-grade testing, AI metabolic analysis and personalized health management into a complete “Testing × AI × Wellness” loop, addressing the growth opportunity of the GLP-1 generation and the longevity economy.

02

Brand e-commerce × CDMO dual engine

Gradually shifting from traditional distribution toward higher-value brand e-commerce and CDMO services, deepening direct relationships with consumers while offering custom medical-device development to partners.

03

International tech & regulatory expansion

Continuing to strengthen R&D of the AI analysis and recommendation engine, and advancing technical and regulatory readiness in international markets to lay the foundation for PixoTech® in broader markets.

Investor relations
contact

If you have questions about the company's operations, finances or shareholder matters, please contact us through the channel below. We will respond following the principle of fair disclosure.

Spokesperson · IR contact
Eliza Huang, Associate VP, Finance
+886-2-8751-1335
info@ixensor.com
6F., No.9, Aly. 2, Ln. 35, Jihu Rd., Neihu Dist., Taipei

Important notice: The information on this page is for reference only and does not constitute investment advice or an offer. The company's financial and business information is governed by the content officially announced on MOPS as required by law. Investors should make their own decisions and bear their own risk. This page contains no financial forecasts or operational-outlook figures that have not been publicly disclosed.